TY  - JOUR
AU  - Nelson, Peter T
AU  - Lee, Edward B
AU  - Cykowski, Matthew D
AU  - Alafuzoff, Irina
AU  - Arfanakis, Konstantinos
AU  - Attems, Johannes
AU  - Brayne, Carol
AU  - Corrada, Maria M
AU  - Dugger, Brittany N
AU  - Flanagan, Margaret E
AU  - Ghetti, Bernardino
AU  - Grinberg, Lea T
AU  - Grossman, Murray
AU  - Grothe, Michel J
AU  - Halliday, Glenda M
AU  - Hasegawa, Masato
AU  - Hokkanen, Suvi R K
AU  - Hunter, Sally
AU  - Jellinger, Kurt
AU  - Kawas, Claudia H
AU  - Keene, C Dirk
AU  - Kouri, Naomi
AU  - Kovacs, Gabor G
AU  - Leverenz, James B
AU  - Latimer, Caitlin S
AU  - Mackenzie, Ian R
AU  - Mao, Qinwen
AU  - McAleese, Kirsty E
AU  - Merrick, Richard
AU  - Montine, Thomas J
AU  - Murray, Melissa E
AU  - Myllykangas, Liisa
AU  - Nag, Sukriti
AU  - Neltner, Janna H
AU  - Newell, Kathy L
AU  - Rissman, Robert A
AU  - Saito, Yuko
AU  - Sajjadi, S Ahmad
AU  - Schwetye, Katherine E
AU  - Teich, Andrew F
AU  - Thal, Dietmar R
AU  - Tomé, Sandra O
AU  - Troncoso, Juan C
AU  - Wang, Shih-Hsiu J
AU  - White, Charles L
AU  - Wisniewski, Thomas
AU  - Yang, Hyun-Sik
AU  - Schneider, Julie A
AU  - Dickson, Dennis W
AU  - Neumann, Manuela
TI  - LATE-NC staging in routine neuropathologic diagnosis: an update.
JO  - Acta neuropathologica
VL  - 145
IS  - 2
SN  - 0001-6322
CY  - Heidelberg
PB  - Springer
M1  - DZNE-2023-00030
SP  - 159 - 173
PY  - 2023
AB  - An international consensus report in 2019 recommended a classification system for limbic-predominant age-related TDP-43 encephalopathy neuropathologic changes (LATE-NC). The suggested neuropathologic staging system and nomenclature have proven useful for autopsy practice and dementia research. However, some issues remain unresolved, such as cases with unusual features that do not fit with current diagnostic categories. The goal of this report is to update the neuropathologic criteria for the diagnosis and staging of LATE-NC, based primarily on published data. We provide practical suggestions about how to integrate available genetic information and comorbid pathologies [e.g., Alzheimer's disease neuropathologic changes (ADNC) and Lewy body disease]. We also describe recent research findings that have enabled more precise guidance on how to differentiate LATE-NC from other subtypes of TDP-43 pathology [e.g., frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS)], and how to render diagnoses in unusual situations in which TDP-43 pathology does not follow the staging scheme proposed in 2019. Specific recommendations are also made on when not to apply this diagnostic term based on current knowledge. Neuroanatomical regions of interest in LATE-NC are described in detail and the implications for TDP-43 immunohistochemical results are specified more precisely. We also highlight questions that remain unresolved and areas needing additional study. In summary, the current work lays out a number of recommendations to improve the precision of LATE-NC staging based on published reports and diagnostic experience.
KW  - Dementia
KW  - Humans
KW  - Alzheimer Disease: pathology
KW  - Frontotemporal Dementia: pathology
KW  - Amyotrophic Lateral Sclerosis: pathology
KW  - DNA-Binding Proteins: genetics
KW  - TDP-43 Proteinopathies
KW  - DNA-Binding Proteins (NLM Chemicals)
KW  - Aging (Other)
KW  - Dementia (Other)
KW  - FTD (Other)
KW  - Hippocampal sclerosis (Other)
KW  - NCI (Other)
KW  - Neuroanatomy (Other)
KW  - Processes (Other)
KW  - Stages (Other)
KW  - TDP-43 (Other)
LB  - PUB:(DE-HGF)16
C2  - pmc:PMC9849315
C6  - pmid:36512061
DO  - DOI:10.1007/s00401-022-02524-2
UR  - https://pub.dzne.de/record/169151
ER  -